Spleen tyrosine kinases: biology, therapeutic targets and drugs
- PMID: 20553955
- DOI: 10.1016/j.drudis.2010.05.001
Spleen tyrosine kinases: biology, therapeutic targets and drugs
Abstract
Spleen tyrosine kinase (Syk) is an intriguing protein tyrosine kinase involved in signal transduction in a variety of cell types, and its aberrant regulation is associated with different allergic disorders and antibody-mediated autoimmune diseases such as rheumatoid arthritis, asthma and allergic rhinitis. Syk also plays an important part in the uncontrolled growth of tumor cells, particularly B cells. For these reasons, Syk is considered one of the most interesting biological targets of the last decade, as proved by the great number of papers and patents published, and the possibility of treating these pathologies by means of Syk kinase inhibitors has led to a great interest from the pharmaceutical and biotech industry.
2010 Elsevier Ltd. All rights reserved.
Similar articles
-
Therapeutic prospect of Syk inhibitors.Expert Opin Ther Pat. 2009 Oct;19(10):1361-76. doi: 10.1517/13543770903207039. Expert Opin Ther Pat. 2009. PMID: 19670961 Review.
-
Inhibitors of switch kinase 'spleen tyrosine kinase' in inflammation and immune-mediated disorders: a review.Eur J Med Chem. 2013 Sep;67:434-46. doi: 10.1016/j.ejmech.2013.04.070. Epub 2013 Jul 12. Eur J Med Chem. 2013. PMID: 23917087 Review.
-
Spleen tyrosine kinase inhibitors: a review of the patent literature 2010 - 2013.Expert Opin Ther Pat. 2014 May;24(5):573-95. doi: 10.1517/13543776.2014.890184. Epub 2014 Feb 20. Expert Opin Ther Pat. 2014. PMID: 24555683 Review.
-
[Syk inhibitors].Nihon Rinsho. 2013 Jul;71(7):1248-52. Nihon Rinsho. 2013. PMID: 23961675 Review. Japanese.
-
Selective inhibition of spleen tyrosine kinase (SYK) with a novel orally bioavailable small molecule inhibitor, RO9021, impinges on various innate and adaptive immune responses: implications for SYK inhibitors in autoimmune disease therapy.Arthritis Res Ther. 2013 Oct 4;15(5):R146. doi: 10.1186/ar4329. Arthritis Res Ther. 2013. PMID: 24286216 Free PMC article.
Cited by
-
Intracellular Signaling Pathways in Rheumatoid Arthritis.J Clin Cell Immunol. 2013 Aug 19;4:160. doi: 10.4172/2155-9899.1000160. J Clin Cell Immunol. 2013. PMID: 24619558 Free PMC article.
-
Therapy: Spleen tyrosine kinase inhibitors--novel therapies for RA?Nat Rev Rheumatol. 2011 Mar;7(3):134-6. doi: 10.1038/nrrheum.2011.8. Epub 2011 Feb 8. Nat Rev Rheumatol. 2011. PMID: 21304505
-
Kinase inhibitors: a new class of antirheumatic drugs.Drug Des Devel Ther. 2012;6:245-50. doi: 10.2147/DDDT.S25426. Epub 2012 Sep 21. Drug Des Devel Ther. 2012. PMID: 23055694 Free PMC article. Review.
-
Cancer genomics: from discovery science to personalized medicine.Nat Med. 2011 Mar;17(3):297-303. doi: 10.1038/nm.2323. Nat Med. 2011. PMID: 21383744
-
The adaptor 3BP2 is required for early and late events in FcεRI signaling in human mast cells.J Immunol. 2012 Sep 15;189(6):2727-34. doi: 10.4049/jimmunol.1200380. Epub 2012 Aug 15. J Immunol. 2012. PMID: 22896635 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Miscellaneous